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Abstract
This study examined the cardiac and vasomotor responses to submaximal handgrip exercise and
beta-adrenergic control in carriers (n = 6) and non-carriers (n = 4) of a genetic variant of
adenylyl cyclase 6 (AC S674). Rhythmic handgrip contractions (1 minute bout; 2 second
contraction-relaxation period) were performed at three different intensities (20, 40, and 60% of
maximal voluntary contraction force) to test the vasodilatory response to exercise. Additionally,
two 5 minute infusions of isoproterenol (0.01 and 0.02 µg·kg-1·min-1 diluted in 5% dextrose) and
one 10 minute infusion of propranolol (0.1 mg·kg-1 diluted in 0.9% saline) were used to examine
beta-adrenergic mediated cardiovascular responses. Ascending aorta and brachial artery mean
blood flow velocities (pulsed Doppler ultrasound) and brachial artery blood pressure (Finometer)
were continuously measured during handgrip and pharmacological protocols. Vascular
mechanics of the forearm were calculated using a three-element lumped windkessel model. At
baseline, AC S674 carriers have decreased systemic vascular conductance and forearm vascular
bed compliance, as well as increased pulse pressure. However, AC S674 carriers did not exhibit
altered cardiac or vasomotor control during handgrip exercise, isoproterenol infusion, or
propranolol infusion. These results indicate that expression of the dysfunctional genetic variant
AC S674 has profound effects on systemic hemodynamics at rest. Chronic elevation in vascular
contractile state may result in vascular stiffening and enhanced pulse pressures with detrimental
long-term consequences for cardiovascular health.
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Chapter 1
1. Introduction
The human cardiovascular system is a progression of vessels arranged in parallel and in
series. Oxygenated blood is ejected from the left ventricle into the aorta and dispersed through
arteries, arterioles and capillaries of the systemic circulation before venous return to the right
atrium. The flow of blood to any tissue in the human body depends on perfusion pressure (i.e.
mean arterial pressure) and vascular tone (i.e. resistance; Delp, 1998). Perfusion pressure is
regulated by feedback control systems that rely on autonomic nerves and circulating hormones
(Dampney, 2002). Vascular tone is influenced by sympathetic vasomotor nerve activity,
circulating vasoactive hormones, and local factors such as metabolites and endothelial factors
(Clifford, 2011). The fundamental purpose of cardiovascular control is to maintain homeostasis
by matching blood flow to the metabolic demands of all tissues within the body.
Blood flow to contracting skeletal muscle increases rapidly at the onset of voluntary
submaximal exercise to meet the metabolic requirements of that muscle. This exercise hyperemic
response is achieved through an increase in cardiac output and vasodilation of the exercising
skeletal muscle vascular bed (Dampney, 2002). Cardiac output increases due to elevations in
heart rate and stroke volume (Åstrand, 1964; Hermansen, 1970; Eriksen, 1990; Rowell, 1993).
However, despite over 100 years of research, summarized in several reviews (Saltin, 1998;
Clifford, 2004; Joyner, 2007; Saltin, 2007, Clifford, 2011), considerable uncertainty remains
regarding the vasodilatory mechanisms responsible for vasomotor control and blood pressure
regulation during exercise.
Adenylyl cyclase (AC) is a G-protein-coupled enzyme that reduces intracellular calcium
within vascular smooth muscle. Adenylyl cyclase catabolizes intracellular ATP into cyclic AMP
(cAMP) via beta-adrenergic stimulation of the Gαs protein. Elevated levels of cAMP produce a
decrease in intracellular calcium and subsequent relaxation of vascular smooth muscle. Recently,
a dysfunctional variant of the adenylyl cyclase 6 isoform (AC S674) has been identified in
humans (Gros, 2005) Expression of the AC S674 variant correlates with greater venous dilation
in response to beta-adrenergic stimulation, and increased post-exercise hyperemia to volitional
handgrip exercise (Gros, 2007; Hodges, 2010). Therefore, the enhanced vasodilatory capacity of
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AC S674 carriers may provide further insight into the mechanisms responsible for exercise
hyperemia.
Adenylyl cyclase is activated via β1 (cardiac) and β2 (vascular smooth muscle) receptor
stimulation and therefore contributes to neurogenic vasomotor control. Vascular resistance, or its
inverse of conductance, reflects the state of vascular contraction and alters blood flow to a
vascular bed through changes in arterial diameter. However, the concept of vascular resistance
involves steady state flow and does not account for the pulsatile nature of blood flow (Zamir,
2007). Recent evidence has suggested that compliance is an independent variable that deserves
consideration when examining vasomotor regulation in skeletal muscle (Zamir, 2007; Frances,
2011). The study of vascular bed mechanics is integral to understanding vasomotor control and
blood flow to skeletal muscle.

1.2 Purpose
The primary purpose of this study was to investigate the cardiac and vasomotor responses to
beta-adrenergic control in carriers and non-carriers of the variant AC S674. The second purpose
of this study was to examine the impact of the AC S674 variant to vasomotor control during
submaximal handgrip exercise.

1.3 Hypothesis
This study tested the hypothesis that individuals who express the AC S674 variant will: 1)
express increased vasodilatory and tachycardia response to beta-adrenergic activation, and; 2)
have a greater vasodilatory response to handgrip exercise.
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Chapter 2
2. Literature Review
2.1 Blood Pressure
Blood pressure at any location of the vasculature encompasses three components: 1)
static pressure that is related to the volume of blood within the vascular system at zero flow; 2)
hydrostatic pressure caused by the force of gravity and referred to as pgh, where p is fluid
density, g is the acceleration due to gravity, and h is the height of the hydrostatic column, and; 3)
dynamic pressure generated by the heart is equal to blood flow x resistance (Rowell, 1993). The
last component alone is responsible for the movement of blood and is commonly referred to as
‘blood pressure’.

2.1.2 Systemic Vasculature & Blood Pressure
The rhythmic beating of the left ventricle creates a pulsatile pressure waveform that is
propagated throughout the systemic vasculature. This pressure waveform is regulated by arterial
structure and mechanical components (i.e. elastin and collagen). Each region of the systemic
vasculature serves a different function: 1) the large central elastic arteries (e.g. aorta, carotid etc.)
act as a cushioning reservoir that stores blood during systole and eject blood to the periphery
during diastole; 2) muscular arteries (e.g. brachial, femoral) serve as long conduits to transport
blood to the periphery and organs, and; 3) high resistance arterioles that maintain mean arterial
pressure and modulate steady state blood flow to vascular beds.
As the pressure waveform generated by the heart travels to the periphery, local systolic
and pulse pressures increase. However, diastolic and mean pressures decrease when moving
from central to peripheral vascular segments due to the progressive increase in arterial stiffness,
and arterial branching that reduces overall vascular resistance (Nichols & O'Rourke, 2005). The
total pressure waveform recorded at any location of the arterial tree is the sum of the forward
wave produced by left ventricular ejection, and the backward traveling wave that is reflected at
peripheral sites (Agabiti-Rosei, 2007). Potential wave reflection sites include branching points,
areas of altered arterial elastance, and the high-resistance arterioles (Nichols & O’Rourke, 2005).
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Thus, the pressure wave becomes increasingly altered as it moves farther away from the aorta in
the circulation.

2.1.3 Blood Pressure and Blood Flow
The systemic arterial tree acts as a closed loop circuit consisting of thousands of
cylindrical tubes. As such, many scientists began to apply the principles of fluid mechanics to
better understand the relationship between blood pressure and flow. Jean Louis Poisseuille
(1846) was the first hemodynamic scientist to establish that flow in a tube was related to the
fourth power of the tube’s internal radius. Poiseuille’s Law is:

where P1 – P2 is the pressure change in the tube, Q is the volumetric flow rate, µ is the dynamic
viscosity, L is the length of the tube, and r is the radius of the tube.
Additionally, Georg Simon Ohm (1827) stated that the current through a conductor
between two points is directly proportional to the potential difference across two points. The
inclusion of resistance to this principle ended with the development of Ohm’s Law:

where I is the current through the conductor, V is the potential difference measured across the
conductor, and R is the resistance of the conductor. Applied to the cardiovascular system, Ohm’s
law is transformed:

where Q is the volumetric flow rate of blood, P1 – P2 is the pressure drop across the artery, and R
is the resistance to blood flow in the artery. Therefore, a direct relationship can be made between
vascular contractile state and blood flow in the cardiovascular system.
Due to Poisseuille and Ohm’s equations consisting of similar variables, Poisseuille’s law
can be altered to the following:

where R is the resistance to blood flow in the artery, µ is the dynamic viscosity of blood, L is the
length of the vessel, and r is the radius of the vessel. In fluid mechanics pressure is the driving
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force behind flow. Blood flow will travel from areas of high pressure (arteries) to areas of low
pressure (veins). Furthermore, changes in artery radius will create the largest flow responses in
the vasculature. Dilation in an artery or vascular bed will reduce resistance thereby increasing
blood flow.
Vascular conductance is the inverse of resistance and is defined as the ability for a fluid
to flow through a conduit per unit pressure difference:

where R is the resistance to blood flow in the artery, and VC is the conductance of blood through
the artery. When substituted into Ohm’s equation for blood flow, the resultant equation is:

where VC is the conductance of blood through the artery, Q is the volumetric flow rate of blood,
and P1 – P2 is the pressure drop across the artery. Similar to resistance, an increase in arterial
diameter (thereby decreasing resistance and increasing flow) will produce a large change in
vascular conductance.
The study of hemodynamics has elucidated the strong relationship between pressure and
flow. Pressure is the driving force behind flow in the arterial system and especially through
vascular beds. During exercise, muscular contractions squeeze blood out of the venous
capacitance vessels thereby enhancing the arterial- venous (P1 – P2) pressure difference and
along with elevated vascular conductance (through arterial vasodilation) drive flow through the
vascular bed (Rowell, 1993).

2.2 Arterial Blood Flow
The physics that govern Poisseuille and Ohm’s laws concern oscillatory flow through
rigid tubes of constant diameters. However, arteries are viscoelastic tubes whose diameters
fluctuate with pulsating pressures that are generated by pulsatile flows from the left ventricle
(Sonesson, 1994). As such, the arterial system has been modeled in a number of different ways
to study hemodynamics: tube models, anatomically based distribution models, and lumped
models (Westerhof, 2009). The arterial Windkessel model was first proposed by Stephen Hales
to account for the pulsatile nature of blood flow. The arteries act as a cushion that converts
pulsatile flow from the heart into steady state flow through vascular beds. Thus, the Windkessel
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model is a lumped model that describes the pressure-flow relationship of the whole arterial
system from its entrance.

2.2.1 The Arterial Windkessel
The first arterial Windkessel model was developed by Otto Frank to determine the
resistance (R, total peripheral resistance) and compliance (C) of the systemic vascular bed based
on aortic measurements (Westerhof, 2009). However, it is now known that the pulsatile
mechanics of flow through a vascular bed are additionally influenced by viscoelasticity (K) and
inertance (L; Zamir 2007). Together, R (resistance due to viscous drag at the vessel wall); C, and
K (due to viscoelastic opposition to stretch of the vessel wall); and L (inertia of the blood and
vessel wall) compose a modified four element lumped Windkessel used to predict flow in a
peripheral vascular bed (Zamir, 2007; Zamir, 2009; Frances, 2011).

2.2.2 The RCKL Model
Flow into a vascular bed relies on both steady state (R) and oscillatory (C, K, and L)
components (Zamir, 2009). R is obtained by simultaneously measuring mean pressure and mean
flow at the point of entry to a vascular bed (Zamir, 2009). Additionally, the values of C, K, and L
are calculated from the simultaneous measurement of oscillatory pressure and flow at the
vascular bed entry point (Zamir, 2009). For a given set of values (C, K, and L), the model
predicts a flow wave that would be produced by a measured pressure wave during pulsatile flow
(Zamir, 2007). The most accurate model can be determined by the lowest error value that is
determined by the sum of the differences squared between the two waveforms at each point
along the wave (Nielson, 2011). The process is automated using MATLAB software and
techniques of fast Fourier transform (Brigham, 1988; Figure 2.1).
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A.

C.

B.

D.

Figure 2.1 The RCKL Model A. ECG, pressure, and flow channels; B. Mean pressure waveform
(top) and mean flow waveform (bottom); C. R (mean pressure and flow) is measured in parallel
to C, K, and L (oscillatory pressure and flow) at the vascular bed point of entry; D. Predicted
flow wave (dashed-line) and measured flow wave (solid) with values of R, C, K, and L
displayed.
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2.2.3 Vascular Bed Mechanics & Vasomotor Control
The steady state component of blood flow regulation to skeletal muscle vascular beds is
controlled by vascular resistance (or its inverse of vascular conductance) and perfusion pressure.
However, arterial compliance plays an integral role in the mechanics of pulsatile flow.
Compliance reflects the elasticity of the arterial wall, but can be affected by vascular smooth
muscle (VSM) contractile state and, therefore neural innervation (Grassi, 1995). For example,
relaxation of VSM has been shown to cause increased compliance in the brachial artery and
forearm (Fitchett, 1984; Safar, 1987). Recent research from our laboratory has confirmed the
importance of compliance as a regulatory variable in vasomotor control. Specifically, Zamir
(2007) examined the forearm vascular bed and reported increased compliance with arm elevation
(relative to the heart), and decreased compliance as a result of lower body negative pressure or a
cold pressor test. In a follow-up study conducted by Frances (2011), adrenergic activation via
noradrenaline infusion decreased forearm vascular bed compliance. In addition to alpha
adrenergic receptors, beta adrenergic receptors contribute a dilatory stimulus to VSM (Garovic,
2002; Eisenach, 2004). Beta-adrenergic control exerts its effect through the adenylyl cyclase
enzyme. Very little research has been conducted on the role of this enzyme in either vasomotor
responses to exercise or vascular mechanics.

2.3 Vasodilation and Hyperemia
Numerous reviews have examined the vasodilatory mechanisms responsible for exercise
hyperemia ( Saltin, 1998; Clifford, 2004; Joyner, 2007; Saltin, 2007; Clifford 2011). The
classical view is that there is an interaction between numerous vasodilatory mechanisms (lactate,
H+ ions, oxygen, ATP and adenosine, nitric oxide, prostaglandins, and endothelial derived
hyperpolarizing factor) released via skeletal muscle, endothelium, and erythrocytes that
contribute to hyperemia. Essentially, vasodilation is the result of processes decreasing
concentrations of intracellular calcium within vascular smooth muscle cells (Clifford, 2004). The
enzyme adenylyl cyclase is a regulator of intracellular calcium within vascular smooth muscle
(Figure 2.2). However, only one study to date, from our group, has examined the effects of
adenylyl cyclase on exercise hyperemia in humans (Hodges, 2010).
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Figure 2.2 Adrenergic mediated pathways of adenylyl cyclase in a vascular smooth muscle cell.
β2 receptor activation activates adenylyl cyclase to convert ATP into cAMP producing a decrease
in intracellular calcium, inhibition of Phopholipase C, relaxation of vascular smooth muscle, and
a consequent arterial vasodilation. (DAG, diacylglycerol; IP3, inositol triphosphate; SR,
sarcoplasmic reticulum; reprinted with permission from K. Shoemaker).

2.3.1 Adenylyl Cyclase
Adenylyl cyclase (AC) is a ubiquitous enzyme that catalyses the conversion of
intracellular ATP to cAMP. The adenylyl cyclases are large (1 080 – 1 248 amino acids)
polypeptides that cross the plasma membrane 12 times in two cassettes of six transmembrane
spanning domains; each individual cassette is followed by a large cytosolic domain (Figure 2.3;
Cooper, 1995; Patel, 2001).
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Figure 2.3 Schematic of the proposed structure for membrane bound adenylyl cyclase. The AC
enzyme is composed of two transmembrane regions (M1 and M2) combined with two
cytoplasmic domains (C1 and C2; Patel, 2001; reprinted with permission).
The structure of AC allows for extracellular (via αi, αs, and βγ subunits of G proteincoupled receptors) and intracellular (via protein kinases, phosphatases, calcium, and
calcium/calmodulin) interactions to occur (Cooper, 1995; Hanoune, 2001; Gros, 2005). The two
cytosolic domains of AC constitute the catalytic site and are regulated by varying concentrations
of ions such as calcium and magnesium (Hurley, 1999). Due to these many interactions, AC has
been proposed to be the rate-limiting step in the G protein-coupled receptor-signaling cascade
(Ostrom, 2012).

2.3.2 Adenylyl Cyclase Isoforms
Currently, there are nine membrane bound isoforms (AC1-9) and one soluble form of
mammalian AC that have been characterized and separated into three different groups (Group 1:
AC1, AC3, AC8; Group 2: AC2, AC4, AC7; and Group 3: AC5 and AC6; Defer, 2000;
Hanoune, 2001; Patel, 2001). The additional soluble AC is the predominant form in mammalian
sperm and is classified separately (Wuttke, 2001). All of the AC isoforms share a large sequence
homology in the primary structure of the catalytic site. However, the catalytic sites of each
isoform have a specific pattern of regulation by G proteins, calcium/calmodulin, and protein
kinases (Defer, 2000; Hanoune, 2001; Ostrom, 2012). These distinct properties allow AC
isoforms to play an interpretive role in signal transduction as opposed to a linear activation
pathway of G protein-coupled receptors. Therefore, external signal integration from G proteincoupled receptors depends on the properties and relative level of isoform expression in tissues
(Cooper, 1995; Defer, 2000). Although there are many isoforms and regulatory processes, the
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resultant end product of all adenylyl cyclase isoforms is the same (i.e. an increase in intracellular
cAMP; Ostrom, 2012).

2.3.3 Adenylyl Cyclase: Genetic Variants
Genetic variants have been described for a variety of G proteins and G protein-coupled
receptors linked to adenylyl cyclase (Rana, 2001). Expression of these genetic variants leads to
alterations in receptor-mediated activation of adenylyl cyclase in addition to alterations in
downstream effector pathways. Currently, the identification of dysfunctional genetic variants has
been limited to isoforms AC3, AC6 and AC9 (Ikoma, 2003; Small, 2003). The AC6 isoform is
the predominant adenylyl cyclase in the human adult left ventricle and is a critical regulator in
vascular smooth muscle (Wang, 2004; Gros, 2006). Furthermore, the expression of a genetic
variant of AC6 that alters AC6 function could lead to modified vascular adenylyl cyclasemediated effects (Gros, 2007).

2.3.4 Adenylyl Cyclase 6 Variant
The AC6 variant results from a single nucleotide polymorphism in intron 17 of the gene
that codes for the normal AC6 isoform (Gros, 2005). This variant was originally discovered in a
population of Japanese individuals (Ikoma, 2003). Further research concluded that a missense
mutation occurred at amino acid 674 within the AC6 catalytic domain (Gros, 2005). This AC6
variant has a genotypic frequency of approximately 6% in Caucasians and is referred to as AC
S674 (Gros, 2005).
Recent research has concluded that AC S674 is a hyperfunctional variant compared to the
more common wild type AC A674. Gene transfer of AC S674 to rat vascular smooth muscle
cells resulted in increased AC activity and arborization (Gros, 2007). Isolated mononuclear
leukocyte cells from humans expressing AC S674 displayed significantly increased AC activity
and AC-mediated cell retraction (Gros, 2007). Additionally, the expression of AC S674 in
humans correlated with: 1) increased AC enzymatic activity and; 2) enhanced AC-mediated
vasodilation to isoproterenol as measured by a dorsal vein linear variable differential transformer
(Gros, 2007). In regards to blood flow control, human carriers of AC S674 expressed greater
post-exercise forearm blood flow responses to isometric handgrip exercise (Hodges, 2010).
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However, the direct effect of AC S674 stimulation or inhibition on human cardiac and vasomotor
control remains to be elucidated.

2.3.5 Beta-Adrenergic Control
Adenylyl cyclase is stimulated when the heterotrimeric G protein, Gαs, is activated by
epinephrine or norepinephrine binding to β1 or β2 adrenergic receptors (Saucerman, 2003). The
activation of β1 and, to a lesser extent, β2 receptors in the heart produces an overall increase in
cardiac output. The increase in cardiac output is a combination of increased cardiac stimulation
(β1; positive inotropy, lusitropy, and chronotropy) and myocardial contractility (β2; Katz, 2011).
As mentioned previously (Figure 2.2), the activation of β2 receptors in VSM produces a
relaxation of smooth muscle and subsequent arterial vasodilation. Conversely, beta-adrenergic
antagonists prevent epinephrine and norepinephrine from binding to β1 and β2 receptors. When
this occurs, AC is deactivated and results in diminished physiological responses (i.e. decreased
heart rate; Katz, 2011). Thus, beta-adrenergic mediated regulation of AC is imperative for both
cardiac and vasomotor control.

2.4 Blood Flow Measurements
Blood flow to a vascular bed increases in proportion to the metabolic demands of the
active muscle tissue (Andersen & Saltin, 1985). Measurement of arterial inflow is necessary to
accurately assess the hyperemic response in exercising limbs. Regional limb blood flow
measurements have previously been conducted via electromagnetic flow meters,
plethysmography, intravascular indicators (e.g. thermodilution), Doppler ultrasound, and
magnetic resonance imaging (Rådegran, 1999). Recently, Doppler ultrasound has become the
preferred modality to measure blood flow to exercising limbs.

2.4.1 Doppler Ultrasound
Ultrasound is defined as a mechanical vibration with a frequency ( f ) above the range of
human hearing. Ultrasound measurements calculate the Doppler frequency shift (Δf ) that occurs
as sound waves are reflected by erythrocytes (Gill, 1979). More simply defined, Δf is the
transmitted frequency (fT) minus the received frequency (fR):
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Thus, blood velocity can be described as positive (towards the transducer) or negative (away
from the transducer). The Doppler equation is used to detect blood velocity:

where Δf is the change in frequency received by the transducer, v is the velocity of erythrocytes,
θ is the angle between the axis of the beam and direction of flow (insonation angle), and c is the
velocity of sound in blood (approximately 1540 m/s; Radegran, 1999; Wood, 2010). The
insonation angle must be below 60° for accurate assessment of blood flow measurements.
Angles greater than 60° will provide an amplified error when blood flow is calculated from the
velocity profile.
The strength of Doppler ultrasound is that it provides a continuous, non-invasive estimate
of beat-to-beat blood velocity (Shoemaker, 1996). Coupled with the cross-sectional area of the
examined artery (e.g. brachial artery), limb blood flow can be calculated at rest, at onset of and
during submaximal exercise, as well as post-exercise (Radegran, 1999). Additionally, Doppler
ultrasound during rest and exercise has proven to be a reproducible and reliable modality to
assessing blood flow control (Shoemaker, 1996).

2.5 Brachial Artery Pressure Measurements
The FinometerTM allows for the continuous, non-invasive collection of arterial pressure.
Arterial pressures are obtained from a cuff that is placed around the intermediate phalanx of the
middle finger. Specifically, the FinometerTM calculates arterial pressure via the volume clamp
technique and the physiocal set-point criteria (Guelen, 2003; & Guelen, 2008). However, as
mentioned previously, blood pressure and pulse shape vary within the arterial tree. Thus, a
brachial pressure waveform must be remodeled from the pressure waveform obtained in the
finger (Bogert, 2004). The reconstructed brachial artery pressures are sensitive and accurate
representations of brachial artery pressures in a supine position (Guelen, 2003; Schutte, 2003;
Guelen, 2008). Additionally, our laboratory has demonstrated the accuracy of the calculated
brachial artery pressure waveform using handheld tonometry (Zamir, 2007).

14

Chapter 3
3. Methodology
3.1 Ethical Approval
Participants from Western University and the public volunteered to take part in this study
after receiving written and verbal details of the experimental procedures and signing consent
forms approved by The Human Subjects Research Ethics Board at Western University.
Participants were made aware that they could withdraw from the study at any time without
consequence.

3.2 Subjects
A total of 80 Caucasian adults between the ages of 18 and 30 were genotyped to
determine whether they were carriers of the AC6 S674 allele. A 10 mL blood sample was drawn
from the antecubital fossa with the participant in a supine position. The blood sample was put on
ice and transported to the Blackburn Cardiovascular Genetics Laboratory, Western University for
extraction of white blood cells and genotyping. Data on height, weight, and waist circumference
were also obtained. Exclusion criterion included: previously reported cardiovascular, metabolic,
or neurological disease; diabetes; administered prescribed medication that affects autonomic or
cardiovascular function (with the exclusion of oral contraceptives); urinary or digestive
problems; Raynaud’s syndrome, or; pregnancy.
Of the 80 individuals screened, four (two males) participants were identified as
heterozygous carriers for the AC6 S674 variant (henceforth referred to as the AC6 variant
group). An additional six participants (three male) were age-matched from the pool of nonvariant carriers and served as a control group. Oral contraceptive use was documented; however
no standard of timing in regards to menstrual cycle was measured. There were no perceivable
differences between males and females once data was normalized and were therefore pooled.

3.3 Genomic DNA Analysis
Genomic DNA was extracted from whole blood using the Puregene DNA isolation kit
(Gentra Systems, QIAGEN Inc, Mississauga, ON, Canada). Genotyping was performed via
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exon-specific polymerase chain reaction (PCR) amplifications in the AC6 gene (Gros, 2005).
PCR amplifications were completed in 30µL mixtures containing 32pmol of each primer; 0.2mM
of each dATP, dCTP, dGTP, DTTP, and; 1.5mM MgCl2, 50mM KCl, 20mM Tris-HCl (pH 8.4),
1.0 units of Taq platinum DNA polymerase (Invitrogen; Life Technologies Corporation,
Carlsbad, California). Thirty cycles were conducted that contained: denaturation at 95°C,
annealing at 60°C ,and extension at 72°C for 30s each; followed by a final extension for 7mins at
72°C and cooling to 4°C. PCR products were purified with CIP/Exol (New England Biolabs,
Pickering, Ontario) and sequenced on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster
City, California). Analysis of DNA sequences was measured by Seq Scape v2.6 (Applied
Biosystems, Foster City, California).

3.4 Experimental Design
3.4.1 Hemodynamics
In the follow-up study to assess cardiovascular control of AC S674, all measurements
were performed with participants in a quiet, darkened room with constant temperature.
Participants reported to the laboratory after a three hour fast and having abstained from caffeine,
alcohol, and exercise for a period of 12 hours. A venous catheter was inserted into a large vein in
the antecubital fossa of the right arm for delivery of pharmacological agents. Heart rate was
recorded via a three lead ECG (Pilot-9200; Colin Medical Instruments, San Antonio, Texas).
Continuous blood pressure measures were obtained from the middle finger of the left hand via
finger cuff plethysmography (FMS Finometer; Finapres Medical Systems, Arnheim,
Netherlands). Finometer measurements of the middle finger were recalculated to produce
brachial artery blood pressure waveforms of the left arm(Schutte, 2003; Bogert, 2004; Bogert &
van Lieshout, 2005). Calculated brachial artery waveforms have previously been shown to
accurately represent true waveforms as assessed by applanation tonometry(Zamir, 2007).
Additionally, brachial blood pressure values were matched to manual sphygmomanometer
measurements of the right arm for consistency.
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3.4.2 Ultrasound
Ultrasound imaging of the ascending aorta and brachial arteries was performed
simultaneously with participants in the supine position. Blood flow velocity of the ascending
aorta (via the suprasternal notch) was assessed by pulsed-wave Doppler ultrasound (2MHz;
Vingmed CFM 750; GE Medical Systems Canada, Mississauga, Canada). Brachial artery
diameters of the right and left arm were obtained using two-dimensional ultrasound imaging
(10MHz; B-Mode ultrasound: GE System 5; GE Healthcare), while pulsed-wave Doppler
ultrasonography (4.7 MHz; GE System 5; GE Healthcare) measured mean blood flow velocities.
All analog signals of hemodynamic and ultrasound data were sampled at 1000Hz and
collected online by the PowerLab data acquisition system (PowerLab 6; ADInstruments, Castle
Hill, Australia). Participants lay supine for a period of 10 minutes before commencement of data
collection.

3.4.3 Handgrip Exercise
Baseline measurements were recorded for 5minutes, followed by three 1minute handgrip
bouts (at 20, 40, and 60% of maximum volitional contraction [MVC]) with 3 minutes between
each bout. Measures of maximal voluntary contraction force were performed 10 minutes prior to
the commencement of baseline measures. The 1 minute bouts of handgrip exercise consisted of a
2 second exercise-relaxation protocol (Figure 3.1). The order of 20 and 40% handgrips was
assigned randomly determined by a coin flip while the 60% handgrip was always conducted last.
The 60% handgrip protocol was performed last to minimize the effect of muscle fatigue on
forearm blood flow. A standardized Borg scale was used to assess perceived exertion after each
exercise bout.

Figure 3.1 Handgrip exercise for 20% MVC indicates the 2 second intermittent contractionrelaxation protocol with Doppler ultrasound collected throughout.
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3.4.4 Cardiac and Vasomotor Control
Previously, venous infusion of isoproterenol has elicited a greater venous dilation in
carriers of the AC S674 variant (Gros, 207). To assess the function of AC S674 on cardiac and
vasomotor control, isoproterenol and propranolol were infused separately through a venous
catheter. Isoproterenol is a non-specific beta-adrenergic agonist and propranolol is a non-specific
beta-adrenergic antagonist. As such, venous infusion of isoproterenol and propranolol allows for
cardiac and vascular smooth muscle responses to occur. Baseline measurements were recorded
for 1minute, followed by two 5 minute infusions of isoproterenol (0.01 and 0.02 µg·kg-1·min-1
diluted in 5% dextrose). Infusion was stopped, and heart rate and blood pressure were monitored
until they returned to pre-isoproterenol baseline. Isoproterenol doses of 0.01 and 0.02 µg·kg1

·min-1 increase heart rate and stroke volume in health y individuals (Edgell, 2007) and these

doses were used here to study both the cardiac and vascular response in both wild type and
ACS674 variants. Isoproterenol infusion was followed by a single dose propranolol infusion (0.1
mg·kg-1 diluted in 0.9% saline) of 10 minutes. Measurements were collected for 1 minute pre
and 5 minutes post-propranolol infusion. Due to the long half-life of propranolol, a single dose
was infused to observe alterations to cardiac and vasomotor function from baseline. A separate
saline trial (0.9% NaCl) was randomly inserted before, between, or after the isoproterenol
infusions via random selection.

3.5 Data Analysis
3.5.1 Stroke Volume
Aortic diameters were measured (Vivid i; GE Healthcare, Mississauga, Canada) and
analyzed using EchoPac Dimension software. Stroke volume was calculated as:
, where SVV is the mean blood flow velocity in the ascending aorta, and AA is the aortic area.
Cardiac output was calculated (CO = HR × SV) and normalized to body surface area (BSA) using
the Du Bois formula (BSA = 0.007184 × W0.425 × H0.725). Subsequently, mean arterial pressure
(MAP = diastolic blood pressure + 1/3 pulse pressure), and systemic vascular conductance (SVC
= CO/MAP) were calculated.
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3.5.2 Forearm Blood Flow
Brachial artery diameters were stored and measured digitally (EchoPac Dimension
software). Three measurements were averaged to acquire a mean value during systole and
diastole to determine brachial artery diameters. Brachial blood flow was calculated as: Flow
(ml/min) =

, where v is the blood velocity, and r is the brachial artery radius

(r = (2/3diastolic diameter + 1/3 systolic diameter)/2) (Radegran, 1997). Blood flow values were
averaged for 10 cardiac cycles at baseline and 2-3 cardiac cycles during the relaxation phases of
handgrip exercise and again immediately post-exercise. Forearm vascular conductance (FVC)
was calculated as limb blood flow divided by MAP. Forearm volume was calculated using the
equation for a truncated cone (V = h[C12 + C1C2 + C2 2] /12π), where V is the volume of the
forearm, C1 is the circumference of the wrist, C2 is the circumference of the widest part of the
forearm at the elbow, and h is the distance between circumference measurements (Taylor, 2006).
Thus, FBF and FVC were normalized to 100 ml of tissue.

3.5.3 Vascular Bed Mechanics
A modified three-element lumped Windkessel model was utilized to quantify forearm
vascular bed mechanics. This model included determination of vascular compliance (C),
viscoelasticity (K) and inertance (L). The value of R was obtained by simultaneously measuring
mean pressure and mean flow at the point of entry to the vascular bed (23). The values of C, K,
and L are calculated from simultaneous measurement of oscillatory pressure and flow at the
vascular bed entry point (23). For a given set of values (C, K, and L), the model predicts a flow
wave that would be produced by a measured pressure wave during pulsatile flow (22).
Additionally, compliance was normalized to 100 ml of forearm tissue.
Ten consecutive cardiac cycles at baseline and during isoproterenol (5mins) and
propranolol (5, 10, and 15mins) were analysed. Data (ECG, brachial pressure, and left arm
brachial flow) were stored and saved in MATLAB format for RCKL program analysis. The
blood pressure and flow waveforms were time-aligned to produce the estimated flow waveform
with the lowest error.
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3.5.4 Statistical Analysis
Baseline hemodynamic and vascular mechanic data were determined by comparing the
mean values of the measured variables using an independent samples t-test. Additionally, the
total change of forearm blood flow (ΔFBF) and forearm vascular conductance (ΔFVC) from rest
to exercise termination was assessed using an independent samples t-test. Moreover, to assess the
changes in forearm blood flow during rhythmic handgrip exercise (handgrip × group), a split-plot
ANOVA was applied for each exercise intensity.
To determine the effect of isoproterenol (dose × group) on cardiac and vascular
measurements, a split-plot (mixed design) analysis of variance (ANOVA) was used. A
Greenhouse-Geisser correction was used to account for violations of sphericity when applicable.
A significant interaction effect prompted the analysis of simple main effects to identify
univariate differences between groups. The total response (Δ = 15 minutes - baseline) in
hemodynamic and vascular mechanic data during propranolol infusion was assessed using an
independent samples t-test. The level of significance for statistical tests was set at p < 0.05. All
data are presented as means ± standard deviation.
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Chapter 4
4. Results
In three separate instances, participant data were excluded from the final analysis of
cardiac and forearm vasomotor control. Firstly, one control participant failed to comply with the
handgrip protocol. Data from this participant were not included in the final calculation of
handgrip responses in the control group. Second, a separate control participant was excluded
from the analysis of forearm vascular bed mechanics because the data were statistically an
outlier. Third, a participant in the AC S674 group did not undergo the pharmacological protocol
because of noticeable baseline bradycardia (33 bpm) causing the concern on the part of the
anesthetist to infuse the pharmacologic agents.

4.1 Baseline Assessment
4.1.1 Anthropometric Measurements
There were no significant differences in anthropometric measurements between groups at
baseline (Table 4.1). However, aortic diameter was significantly smaller in the AC S674 group.
Table 4.1 Anthropometric Measurements
Control (n = 6)
AC S674 (n = 4)
Age (years)
25 ± 2
25 ± 4
Height (cm)
168 ± 6
177 ± 6
Weight (kg)
63 ± 12
69 ± 2
2
BMI (kg·m )
22.1 ± 3.2
22.3 ± 1.1
Waist Circumference (cm)
84 ± 7
86 ± 5
Aortic Diameter (cm)
2.8 ± 0.3
2.1 ± 0.2 *
*Significantly different from controls (p < 0.05). Values are mean ± standard deviation.
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4.1.2 Hemodynamic Measurements
Hemodynamic measurements at baseline were not different during saline infusion. As
such, non-saline values are expressed in Table 4.2. Stroke volume, cardiac output, DBP, MAP
and SVC were decreased in the AC S674 variant group compared to controls (p < 0.05).
Additionally, PP was increased in the AC S674 variant group compared to controls (p < 0.05).
Table 4.2 Baseline hemodynamic characteristics
Control (n = 6)
AC S674 (n = 4)
-1
HR (beats·min )
59 ± 5
48 ± 14
SV (ml·min-1)
112 ± 27
51 ± 13t *
CO (L·min-1·m2)
3.96 ± 1.26
1.42 ± 0.21t *
SBP (mm Hg)
114 ± 8
114 ± 3
DBP (mm Hg)
77 ± 4
62 ± 6 *
PP (mm Hg)
37 ± 7
52 ± 5 *
MAP (mm Hg)
89 ± 5
79 ± 4 *
-1
2
SVC (L·min ·m )
0.045 ± 0.018
0.017 ± 0.002t *
FBF (ml·min-1·100ml-1)
2.21 ± 0.59
2.76 ± 0.83
-1
-1
-1
FVC (ml·min ·100ml ·mm Hg )
0.0248 ± 0.007
0.0345 ± 0.010
HR, heart rate; SV, stroke volume; CO, cardiac output; SBP, systolic blood pressure; DBP,
diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; SVC, systemic
vascular conductance; FBF, forearm blood flow; FVC, forearm vascular conductance. t indicates
sample size of three. Values are mean ± standard deviation.
*Significantly different from controls (p < 0.05).

4.1.3 Forearm Vascular Bed Mechanics
The values of resistance, viscoelasticity and inertia were not significant between the AC
S674 variant group and controls. However, compliance was lower in the AC S674 variant group
compared to controls (p < 0.05; Table 4.3).
Table 4.3 Baseline forearm vascular bed mechanics
Control (n = 5)
AC S674 (n = 4)
R (mm Hg·ml-1·min-1)
5.44 ± 1.46
4.55 ± 1.79
-1
-1
-4
-4
C (ml·mm Hg ·100ml )
9.2 × 10 ± 2.0 × 10
6.8 × 10-4 ± 6.1 × 10-5 *
K (mm Hg·ml-1·min-1)
4.9 × 10-2 ± 2.8 × 10-2
8.7 × 10-2 ± 5.1 × 10-2
-1
2
-5
-5
L (mm Hg·ml ·min )
1.4 × 10 ± 1.1 × 10
1.6 × 10-5 ± 1.5 × 10-5
R, resistance; C, compliance; K, viscoelasticity; L, inertia. Values are mean ± standard deviation.
*Significantly different from controls (p < 0.05).
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4.2 Handgrip Exercise
4.2.1 Forearm Blood Flow
There was no significant group x handgrip interaction effect on FBF. FBF increased
significantly in response to handgrip exercise. This main effect was observed for all levels of
handgrip intensity (20% MVC: p < 0.05, Figure 4.1A; 40% MVC: p < 0.05, Figure 4.3 A; 60%
MVC; p < 0.05, Figure 4.5 A).
The change in FBF from pre- to post-handgrip exercise was not significant between AC
S674 and control groups at each handgrip intensity (p = NS; Figures 4.2, 4.4, and 4.6).

4.2.2 Mean Arterial Pressure
There was no significant group x handgrip interaction effect on MAP. MAP remained
constant throughout all levels of handgrip exercise (p = NS). However, MAP was greater in
controls throughout handgrip exercise at 20 and 40% MVC. This main effect of group was
observed at 20 and 40% MVC (20% MVC: p < 0.05, Figure 4.1 B; 40% MVC: p < 0.05, Figure
4.3 B), but not 60% MVC (p = NS; Figure 4.5 B).

4.2.2 Forearm Vascular Conductance
There was no significant group x handgrip interaction effect on FVC. FVC increased
significantly in response to handgrip exercise. This main effect was observed for all levels of
handgrip intensity (20% MVC: p < 0.05, Figure 4.1 C; 40% MVC: p < 0.05, Figure 4.3 C; 60%
MVC: p < 0.05, Figure 4.5 C).
The change in FVC from pre- to post-handgrip exercise was not significant between AC
S674 and control groups at each handgrip intensity (p = NS; Figures 4.2, 4.4 and 4.6).
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Figure 4.1 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular
conductance (FVC) responses to 20% MVC handgrip exercise in control (n = 5) and AC S674 (n
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. Main effect of group on MAP (p < 0.05);
C. Main effect of handgrip on FVC (p < 0.05). Values are mean ± standard deviation.
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Figure 4.2 ΔFBF (top) and ΔFVC (bottom) to 20% handgrip exercise in control (n = 5) and AC
S674 (n = 4). No significant differences occurred between groups for either FBF or FVC (p =
NS). Values are mean ± standard deviation.
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Figure 4.3 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular
conductance (FVC) responses to 40% MVC handgrip exercise in control (n = 5) and AC S674 (n
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. Main effect of group on MAP (p < 0.05);
C. Main effect of handgrip on FVC (p < 0.05). Values are mean ± standard deviation.
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Figure 4.4 ΔFBF (top) and ΔFVC (bottom) to 40% handgrip exercise in control (n = 5) and AC
S674 (n = 4). No significant differences occurred between groups for either FBF or FVC (p =
NS). Values are mean ± standard deviation.
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Figure 4.5 Forearm blood flow (FBF), mean arterial pressure (MAP), and forearm vascular
conductance (FVC) responses to 60% MVC handgrip exercise in control (n = 5) and AC S674 (n
= 4). A. Main effect of handgrip on FBF (p < 0.05); B. No significant interaction or main effects
observed for MAP (p = NS); C. Main effect of handgrip on FVC (p < 0.05). Values are mean ±
standard deviation.
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Figure 4.6 ΔFBF (top) and ΔFVC (bottom) to 60% handgrip exercise in control ( n = 5) and AC
S674(n = 4). No significant differences occurred between groups for either FBF or FVC (p =
NS). Values are mean ± standard deviation.
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4.3 Cardiac and Vasomotor Control
4.3.1 Heart Rate
There was no significant group x dose interaction effect of isoproterenol on heart rate.
However, there was a main effect of isoproterenol dose on HR. Specifically, HR increased across
isoproterenol doses (p < 0.05; Figure 4.7 C).
The change in heart rate was not significantly different between AC S674 and control
groups throughout propranolol infusion (Figure 4.14 A).

4.3.2 Stroke Volume
There was no significant group x dose interaction effect of isoproterenol on stroke
volume. However, stroke volume was increased in controls compared to AC S674 (p < 0.05,
Figure 4.8 C).
The change in stroke volume was not significantly different between AC S674 and
control groups throughout propranolol infusion (Figure 4.14 B).

4.3.3 Cardiac Output
There was no significant group x dose interaction effect of isoproterenol on cardiac
output. However, there was a main effect of isoproterenol dose on CO. Specifically, CO
increased across isoproterenol doses (p < 0.05; Figure C). There was also a main effect of group
on cardiac output across isoproterenol doses (controls > AC S674; p < 0.05, Figure 4.9 C).
The change in cardiac output was not significantly different between AC S674 and
control groups throughout propranolol infusion (Figure 4.14 C).

4.3.4 Mean Arterial Pressure
There was no significant group x dose interaction effect of isoproterenol on mean arterial
pressure. Additionally, mean arterial pressure was not significantly different across isoproterenol
doses (p = NS; Figure 4.10 C).
The change in mean arterial pressure was not significantly different between AC S674
and control groups throughout propranolol infusion (Figure 4.15 A).
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4.3.5 Systemic Vascular Conductance
There was no significant group x dose interaction effect of isoproterenol on systemic
vascular conductance. Additionally, systemic vascular conductance was not significantly
different across isoproterenol doses (p = NS; Figure 4.11 C).
The change in systemic vascular conductance was not significantly different during
propranolol infusion (p = NS; Figure 4.15 B)

4.3.6 Forearm Blood Flow
There was no significant group x dose interaction effect of isoproterenol on forearm
blood flow. However, there was a main effect of isoproterenol dose on forearm blood flow.
Specifically, forearm blood flow increased across isoproterenol doses (p < 0.05, Figure 4.12 C).
The change in forearm blood flow was not significantly different during propranolol
infusion (p = NS; Figure 4.16 A).

4.3.7 Forearm Vascular Conductance
There was no significant group x dose interaction effect of isoproterenol on forearm
vascular conductance. However, there was a main effect of isoproterenol dose on forearm
vascular conductance. Specifically, forearm vascular conductance increased across isoproterenol
doses (p < 0.05, Figure 4.13 C).
The change in forearm vascular conductance was not significantly different during
propranolol infusion (p = NS; Figure 4.16 B).

4.3.8 Forearm Vascular Bed Mechanics
There were no significant group x dose interaction effect of isoproterenol on resistance,
compliance, viscoelasticity, or inertia. However, resistance decreased across isoproterenol doses
(p < 0.05, Figure 4.17 A). Conversely, compliance increased across isoproterenol doses (p <
0.05, Figure 4.17 B). Additionally, there was a main effect of group on compliance (p < 0.05,
Figure 4.17 B). Specifically, compliance was lower in AC S674 compared to controls.
Viscoelasticity was not significantly different between groups and across isoproterenol doses
(Figure 4.17 C). There was a main effect of isoproterenol dose on inertia (p < 0.05, Figure 4.17
D). Propranolol infusion did not have a significant effect on ΔR, ΔC, ΔK, or ΔL (p = NS; Figure
4.18 and Figure 4.19).
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Figure 4.7 Heart rate (HR) responses to isoproterenol. A. HR response to first isoproterenol dose (0.01µg·kg-1); B. HR response to
second isoproterenol dose (0.02µg·kg-1); C. Maximum HR values obtained during isoproterenol dose one and two. A main effect of
isoproterenol dose on HR occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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Figure 4.8 Stroke volume (SV) responses to isoproterenol. A. SV response to first isoproterenol dose (0.01µg·kg-1); B. SV response to
second isoproterenol dose (0.02µg·kg-1); C. Maximum stroke volume values obtained during isoproterenol dose one and two. A main
effect group on SV occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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Figure 4.9 Cardiac output (CO) responses to isoproterenol. A. CO response to first isoproterenol dose (0.01µg·kg-1); B. COresponse
to second isoproterenol dose (0.02µg·kg-1); C. Maximum CO values obtained during dose one and two. A main effect of isoproterenol
dose on CO occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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Figure 4.10 Mean arterial pressure (MAP) responses to isoproterenol. A. MAP response to first isoproterenol dose (0.01µg·kg-1); B.
MAP response to second isoproterenol dose (0.02µg·kg-1); C. Maximum MAP values obtained during dose one and two. There was
no effect of isoproterenol dose or group on MAP (C; p = NS; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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Figure 4.11 Systemic vascular conductance (SVC) responses to isoproterenol. A. SVC response to first isoproterenol dose
(0.01µg·kg-1); B. SVC response to second isoproterenol dose (0.02µg·kg-1); C. Maximum SVC values obtained during dose one and
two. There was no effect of isoproterenol dose or group on SVC (C; p = NS; controls: n = 6; AC S674: n = 3). Values are means ±
standard deviation.
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Figure 4.12 Forearm blood flow (FBF) responses to isoproterenol. A. FBF response to first isoproterenol dose (0.01µg·kg-1); B. FBF
response to second isoproterenol dose (0.02µg·kg-1); C. Maximum FBF values obtained during dose one and two. A main effect of
isoproterenol dose on FBF occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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Figure 4.13 Forearm vascular conductance (FVC) responses to isoproterenol. A. FVC response to first isoproterenol dose
(0.01µg·kg-1); B. FVC response to second isoproterenol dose (0.02µg·kg-1); C. Maximum values obtained during dose one and two. A
main effect of isoproterenol dose on FVC occurred (C; p < 0.05; controls: n = 6; AC S674: n = 3). Values are means ± standard
deviation.

38
A.

B.

C.

Figure 4.14 Cardiac responses to propranolol infusion. Left: time course response, Right:
change (Δ) from rest to 15 minutes. A. No significant differences between groups on ΔHR; B.
No significant differences between groups on ΔSV; and C. No significant differences between
groups on ΔCO (controls: n = 6; AC S674: n = 3). Values are means ± standard deviation.
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A.

B.

Figure 4.15 Systemic responses to propranolol infusion. Left: time course response, Right:
change (Δ) from rest to 15 minutes. A. No significant difference between groups on ΔMAP; B.
No significant difference between groups on ΔSVC (controls: n = 6; AC S674: n = 3). Values are
means ± standard deviation.
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A.

B.

Figure 4.16 Forearm vascular responses to propranolol infusion. Left: time course response,
Right: change (Δ) from rest to 15 minutes. A. No significant difference between groups on
ΔFBF; B. No significant difference between groups on ΔFVC (controls: n = 6; AC S674: n = 3).
Values are means ± standard deviation.
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A.

B.

C.

D.

Figure 4.17 Maximal forearm vascular bed mechanic responses to isoproterenol. A. Main effect
of isoproterenol on resistance. B. Main effect of isoproterenol on compliance. C. No significant
effect of isoproterenol or group on viscoelasticity. D. Main effect of isoproterenol on inertia
(controls: n = 5; AC S674: n = 3). Values are means ± standard deviation.
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A.

B.

Figure 4.18 Forearm vascular bed mechanic responses to propranolol. Left: time course
response, Right: change (Δ) from rest to 15 minutes. A. No significant difference between
groups on Δ resistance; B. No significant difference between groups on Δ compliance (controls:
n = 6; AC S674: n = 3). Values are means ± standard deviation.
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A.

B.

Figure 4.19 Forearm vascular bed mechanic responses to propranolol. Left: time course
response, Right: change (Δ) from rest to 15 minutes. A. No significant difference between
groups on Δ viscoelasticity; B. No significant difference between groups on Δ inertia (controls: n
= 6; AC S674: n = 3). Values are means ± standard deviation.
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Chapter 5
5. Discussion
The purpose of the present study was to identify the role of AC S674 in cardiac and
vasomotor control. First, compared with non-variant, individuals with AC S674 expressed
decreased baseline cardiac contractility (SV and CO), altered blood pressure characteristics
(decreased DBP, MAP; increased PP), decreased forearm vascular bed compliance, and
increased vasomotor contractile state (decreased SVC). However, neither the systemic nor
forearm responses to beta-adrenergic activation or blockade, nor the exercise-induced dilation
during handgrip, were affected by AC S674. Therefore, the major impact of this adenylyl cyclase
variant appears to affect baseline hemodynamics and not responsiveness to vasoactive stimuli.

5.1 Baseline
The AC S674 genetic variant has been referred to as a hyperfunctional enzyme compared
to the more common AC A674 genotype (Gros, 2007; Hodges, 2010). As such, it is possible that
there is increased activity of the AC S674 enzyme and cAMP production at rest. Additionally,
this increase in AC S674 activity would be expected to promote greater cardiac contractility,
smooth muscle relaxation, enhanced vasodilation of arteries, decreased vasomotor tone and,
therefore, increased vascular conductance. However, the results of the current study indicate the
opposite, as evidenced by decreased cardiac output and vascular bed compliance.
Blood flow to vascular beds within the human body is determined by perfusion pressure
(mean arterial pressure) and vascular contractile state (conductance). However, MAP was
significantly decreased in AC S674 individuals and relied on a reduced SVC to maintain the
same level of blood flow as controls. The three-fold smaller CO at rest in AC S674 individuals
was the determining factor of reduced SVC. In turn, the smaller CO was related first to a smaller
aortic diameter. This is the first report of altered CO and aortic diameter in this variant group and
suggests that a major impact of AC S674 affects cardiac structure. As this finding was
unexpected, additional studies are needed to address this important possibility. Further, the
enhanced PP in this group is consistent with reduced aortic size and indicates an increased
vascular stiffness of the central arteries. This observation is consistent with the diminished
compliance of the forearm vascular bed. For reasons that are not known, the intervening brachial
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artery conductance was not different between groups. Overall, however, the altered cardiac and
vascular structure appears to be a major outcome in this AC variant.
The mechanisms mediating this altered structure remain to be determined, but could
include elevated adrenergic or angiotensin II stimuli. Under baseline conditions, sympathetic
vasomotor nerves regulate arterial pressure and control the distribution of CO at rest (Dampney,
2002). It is possible that AC S674 individuals express greater sympathetic tone or increased
levels of vasoconstrictor metabolites. However, previously observed baseline levels of
norepinephrine were similar in AC S674 variant individuals and non-variants (Hodges, 2010).
Additionally, elevated angiotensin II could also affect cardiac and vascular structure and
mechanics. Importantly, AC S674 carriers were found to have increased levels of circulating
plasma renin (Hodges, 2010). Renin is a crucial enzyme that regulates the production of
angiotensin II, a potent vasoconstrictor. In the current study, reduced SVC in AC S674 could be
a reflection of the chronic effects of increased renin activity, leading to enhanced aldosteronemediated effects on blood volume in addition to possible increased ambient angiotensin IImediated effects (Hodges, 2010).
In the same way that vascular conductance (or resistance) influences steady state flow, a
change in compliance affects the impedance of the vascular bed in pulsatile flow. Additionally,
arterial compliance is influenced by vascular smooth muscle contractility and is an indicator of
vasomotor control (Zamir, 2007). In the present study, baseline forearm vascular bed compliance
was lower in AC S674 individuals. This reduction in compliance may be related to increased
vasomotor tone (Frances, 2011). However, compliance represents the elastic ability of the
arterial wall and, is therefore associated with elastin fibres (Zamir, 2009). Whether this
diminished compliance is due to increased neurogenic vasoconstrictor effects or altered vascular
stiffness remains to be determined.
The AC S674 group consisted of young, physically active individuals free of
cardiovascular abnormalities. It is possible that the cardiac data may vary from general
population due to above-average fitness levels of participants in both groups. However, the longterm effect of chronically reduced SVC and diminished vascular bed compliance is a point of
interest for continued study for this group. Furthermore, AC S674 individuals expressed lower
DBP and greater PP compared to controls. These two variables are the preeminent markers for
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vascular stiffening. Thus, further research is required to determine the cause of increased
vascular resistance in AC S674 individuals.

5.1.1 Methodological Considerations
The hemodynamic profile of the AC S674 group was significantly different compared to
controls. The AC S674 group expressed a significantly lower cardiac output and reduced SVC.
Specifically, the decreased stroke volume in AC S674 was the primary cause for reduced cardiac
output as heart rate was similar between groups. The difference in stroke volume between groups
may be due to a decreased aortic diameter in AC S674 compared to controls. It is not known if
this difference in aortic diameter is a characteristic of the AC S674 population as this is the first
study to measure stroke volume velocity in this cohort. Previously, cardiac output collected via
Finometer has been shown to be increased in AC S674 compared to controls (Hodges, 2010). In
the present study, cardiac output values were based on Doppler ultrasound measures. However,
to contrast the current data with those measured previously, the cardiac output feature of the
Finometer was also measured. This value of cardiac output was similar between groups,
contrasting with the Doppler data. However, calculation of cardiac output from the Finometer
uses the patented ModelFlow algorithm that predicts cardiac stroke volume centred on a transfer
function-based calculation of the aortic pulse pressure assuming a level of aortic compliance
based on age and sex (Pulse Pressure = Stroke Volume/Compliance). An aorta with greater than
expected stiffness will increase the calculated PP and lead to a SV that is erroneously high. This
may be the case in the current study.

5.2 Handgrip Exercise
To our knowledge, this study was the first to examine the effect of adenylyl cyclase on
different levels of submaximal dynamic exercise in humans. In the present study, the hyperemic
response to 20, 40 and 60% dynamic handgrip exercise were not significantly different in AC
S674 and control groups. Specifically, there was no significant difference in either FBF or FVC
kinetics during handgrip exercise at the various intensities. The total response of ΔFBF and
ΔFVC were similar between groups as well. Thus, the genetic variant AC S674 does not produce
enhanced vasodilatory effects in response to dynamic exercise. These observations stand in
contrast to those observed earlier by Hodges . (2010) who also used handgrip exercise. However,
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in that earlier study, the flow was measured during a five second recovery period after a 5 second
handgrip. The regulation of post-exercise blood flow differs from that during more rhythmic
contractions(Shoemaker, 1997; Brock, 1998). Thus, it appears that the AC S674 variant may
exert its vascular effects on the recovery phase of exercise.
Adenosine and prostaglandins stimulate adenylyl cyclase to induce vascular smooth
muscle relaxation and arterial vasodilation during exercise (Joyner, 2007; Clifford, 2011).
Adenosine has been a leading candidate for metabolic vasodilation because it is a potent
vasodilator released from contracting skeletal muscle (Radegran, 2001). As well, arterial infusion
of prostacyclin (a powerful vasodilating prostaglandin) increases blood flow in the human
forearm (Stiegler, 1988). However, recent evidence in humans indicates that not all people
respond to adenosine and that the overall contribution of prostaglandins to exercise blood flow
control remains small (Shoemaker, 1996; Martin, 2007; Joyner, 2007). In the present study,
blood flow responses were similar in AC S674 and control groups. As such, it is hypothesized
that these metabolites did not increase contributions of AC S674 on vasodilation. Further
research must be conducted to assess the functionality of these metabolites on the AC S674
enzyme during exercise.
The requirements of skeletal muscle blood flow directly correlate to metabolic demand.
In addition to adenosine and prostaglandins, nitric oxide, potassium and acetylcholine spillover
contribute to vasodilation in response to active skeletal muscle contraction (Clifford, 2004;
Joyner 2007). This overlap in metabolic pathways makes it difficult to tease out the vasodilator
effects of any individual mechanism, such as adenylyl cyclase. Specifically, neither nitric oxide
nor acetylcholine individually affects the magnitude or rate of increase in FBF exercise
(Shoemaker, 1997). Thus, AC S674 is not the sole determinant of increased skeletal muscle
blood flow during dynamic exercise, as other pathways may up or down regulate their activity to
meet the metabolic requirements of the exercising muscle.
Overall, the current data suggest that the AC S674 enzyme does not exhibit increased
vasodilator effects in response to submaximal dynamic exercise. The similar FBF and FVC
responses in both AC S674 individuals and controls can be explained by the classical “metabolic
milieu” response to exercise. Additional research must be conducted to parse out the overlapping
effects of vasodilator metabolites.
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5.3 Beta-adrenergic Control
Isoproterenol is a non-selective beta-adrenergic agonist that exerts potent stimulation of
β1 and β2 receptors. In the current study, isoproterenol infusion produced significant increases in
HR and CO in both AC S674 and control groups. However, the presence of AC S674 did not
provide an increased cardiac response to isoproterenol infusion. The positive chronotropic effects
of isoproterenol on the heart are consistent with previously reported results in supine humans
(Gortex, 1961). To our knowledge, this was the first study to examine the beta-adrenergic
stimulation of AC S674 in the heart.
Intravenous infusion of isoproterenol primarily elevates FVC in skeletal muscle (Harman
& Limbird, 1996). Forearm vascular bed conductance and compliance increased in both groups
during isoproterenol infusion. These alterations to forearm vascular bed mechanics are indicative
of vascular smooth muscle relaxation. However, FBF and FVC were similar in both groups.
Thus, the AC S674 enzyme did not appear to present increased levels of vasodilation in response
to beta-adrenergic activation.
The above results do not support the hypothesis that this adenylyl cyclase variant would
exert differential beta-adrenergic control of cardiac or vascular function in response to excitatory
or inhibitory stimuli. The determinants of impact for this enzyme over baseline hemodynamics,
but not stimulation-induced changes remain to be determined. Previously, others have observed
differences in venous vasomotor control in this AC variant group (Gros, 2007). However, arterial
and venous smooth muscle responses to beta-adrenergic stimulation are not identical (Stein,
1997). Additional studies examining local artery blood flow and vascular conductance responses
to beta-adrenergic control are warranted.

5.4 Limitations
The focal limitation of the present study is the small sample size of the AC S674 group.
A total of 80 individuals were recruited and analyzed for DNA sequencing. Two participants
were known carriers of the AC S674 variant from previous studies. Therefore, the AC S674
variant prevalence was 2.5% in the current study population compared to a previously reported
7% frequency (Gros, 2005). Due to time constraints and limited resources it was not possible to
identify more carriers for study participation. However, using a two-tailed t-test, p < 0.05, Power
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of 0.80, and effect size of 2.47 describing the difference in SVC between groups, a minimum of
four individuals per group is necessary to replicate this outcome. Therefore, the small sample
size used in this study is sufficient to achieve statistical significance.
Furthermore, it appears that a more comprehensive analysis of the endocrinological and
visceral hemodynamic control is needed to fully characterize the impact of the AC S674 variant
in humans. It would seem important that future studies obtain resting muscle sympathetic nerve
activity (MSNA) in addition to epinephrine, norepinephrine, and plasma renin activity,
angiotensin II, and vasopressin levels to obtain true values of vasomotor tone in AC S674
individuals.

5.5 Conclusion and Perspective
The results of the current study indicate that expression of the dysfunctional genetic
variant AC S674 has profound effects on systemic hemodynamics. At rest, AC S674 individuals
have decreased SVC and vascular bed compliance indicative of elevated vasomotor tone and/or
remodeling. Chronic elevation in vascular contractile state may result in vascular stiffening and
enhanced pulse pressures with detrimental long-term consequences for cardiovascular health.
Specifically, genetic variants of beta-adrenergic receptors and G-proteins are associated with the
development of hypertension(Felder, 2002; Feldman, 2006). Coupled with the results of the
current study, adenylyl cyclase and cAMP production appear to be important factors in the
regulation of cardiovascular health.
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Appendices
Appendix 1A: 20% handgrip exercise
Variable
F Value
η2
FBF (ME HG)
F(3, 21) = 27
0.37
FVC (ME HG)
F(3, 23) = 30
0.47
MAP (ME group)
F(1, 7) = 6
0.43
ME HG, main effect of handgrip; ME group, main effect of group

Significance
p < 0.001
p < 0.001
p = 0.042

Appendix 1B: 40% handgrip exercise
Variable
F Value
η2
FBF (ME HG)
F(3, 20) = 101
0.67
FVC (ME HG)
F(3, 21) = 121
0.75
MAP (ME group)
F(1, 7) = 6
0.41
ME HG, main effect of handgrip; ME group, main effect of group

Significance
p < 0.001
p < 0.001
p = 0.044

Appendix 1C: 60% handgrip exercise
Variable
F Value
FBF (ME HG)
F(3, 18) = 89
FVC (ME HG)
F(3, 19) = 86
ME HG, main effect of handgrip

η2
0.71
0.75

Significance
p < 0.001
p < 0.001

Appendix 2: Isoproterenol dose response
Variable
F Value
HR (ME dose)
F(2,14) = 8
SV (ME group)
F(1, 7) = 48
CO (ME dose)
F(2, 14) = 5
CO (ME group)
F(1, 7) = 6
FBF (ME dose)
F(2,11) = 18
FVC (ME dose)
F(2,11) = 15

η2
0.32
0.85
0.08
0.38
0.44
0.44

Significance
p = 0.003
p < 0.001
p = 0.021
p = 0.040
p < 0.001
p < 0.001

Appendix 3: Manual Blood Pressure Data
Control (n = 6)
SBP (mm Hg)
114 ± 10
DBP (mm Hg)
76 ± 6
Values are mean ± standard deviation.

AC S674 (n = 4)
116 ± 2
71 ± 10
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